Atezolizumab vs Sugemalimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Atezolizumab

Marketed by Roche and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02008227 · Phase 3 · completed

This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong.

Next expected readout: November 2026 · NCT04958811 (registry estimate)

Reported efficacy

Independent Review Facility (IRF)-Assessed Event Free Survival (EFS) (Up to approximately 96 months): IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 (missed)

Result source: NCT03456063

Sugemalimab · Cejemly

Marketed by CStone Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03728556 · Phase 3 · completed

In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07247227 (registry estimate)

Reported efficacy

Progress Free Survival (PFS) (from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months.): Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84 (met)

Result source: NCT03728556

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAtezolizumabSugemalimab
PFS, median7 vs 5.5vs Nab-Paclitaxel+Carboplatinn 456NCT02367781
40 other results
10.5 vs 6.2a+4.3 vs placeboNCT03728556
OS, median13.8 vs 9.6vs Docetaxeln 425NCT02008227
36 other results
—Not posted · NCT03728556
ORR11% vs 10.5%vs Atezolizumab IV1875 mg · n 245NCT03735121
30 other results
—Not posted · NCT03728556
Duration of response, median16.3 vs 6.2vs Docetaxeln 58NCT02008227
33 other results
—Not posted · NCT03728556

PFS, median

Atezolizumab
7 vs 5.5vs Nab-Paclitaxel+Carboplatinn 456NCT02367781
40 other results
Sugemalimab
10.5 vs 6.2a+4.3 vs placeboNCT03728556

OS, median

Atezolizumab
13.8 vs 9.6vs Docetaxeln 425NCT02008227
36 other results
Sugemalimab
—Not posted · NCT03728556

ORR

Atezolizumab
11% vs 10.5%vs Atezolizumab IV1875 mg · n 245NCT03735121
30 other results
Sugemalimab
—Not posted · NCT03728556

Duration of response, median

Atezolizumab
16.3 vs 6.2vs Docetaxeln 58NCT02008227
33 other results
Sugemalimab
—Not posted · NCT03728556
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Atezolizumab: 4 of 4 rows · Sugemalimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAtezolizumabSugemalimab
Dropout rate
n/a: no completion milestonea
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 37 more results
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT02409342 · Phase 3
n/a: no completion milestone
NCT02367781 · Phase 3 · combination
97.9%
NCT03285763 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
100%1875 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
38.5%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
66.7%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
53.3%1200 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03191786 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm A: Atezolizumab + Paclitaxel +
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm B: Atezolizumab + Nab-Paclitax
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
15.8%
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
5.6%
NCT04042558 · Phase 2 · registry result, not featured evidence
—Continuation Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
—Crossover Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
36.5%
NCT02927301 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
16.1%
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
3.1%
NCT03102242 · Phase 2 · registry result, not featured evidence
0%
NCT03526900 · Phase 2 · registry result, not featured evidence
69.3%
NCT02848651 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 1: First Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 2: Second Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 3: Third Line and Beyond At
NCT02031458 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT01903993 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneAtezolizumab (MPDL3280) : 1L Parti
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 1L Part
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 2L+ Bra
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
—Atezolizumab (MPDL3280A) : 2L+ Par
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneRandomized Phase: Daratumumab + At
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestoneSafety Run-in Phase: Daratumumab +
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—
Discontinued due to AEs
—a
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 37 more results
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT02409342 · Phase 3
—
NCT02367781 · Phase 3 · combination
—
NCT03285763 · Phase 4 · registry result, not featured evidence
—
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
—
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
—1875 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
—
NCT03191786 · Phase 3 · registry result, not featured evidence
—
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
0.6%Arm A: Atezolizumab + Paclitaxel +
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Atezolizumab + Nab-Paclitax
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
—
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
—
NCT04042558 · Phase 2 · registry result, not featured evidence
—Continuation Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
—Crossover Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
0%
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
—
NCT02927301 · Phase 2 · registry result, not featured evidence
—
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
—
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
3.1%
NCT03102242 · Phase 2 · registry result, not featured evidence
—
NCT03526900 · Phase 2 · registry result, not featured evidence
—
NCT02848651 · Phase 2 · registry result, not featured evidence
—Cohort 1: First Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
—Cohort 2: Second Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
—Cohort 3: Third Line and Beyond At
NCT02031458 · Phase 2 · registry result, not featured evidence
—
NCT01903993 · Phase 2 · registry result, not featured evidence
9.7%Atezolizumab (MPDL3280) : 1L Parti
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 1L Part
NCT01846416 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280A) : 2L+ Bra
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
—Atezolizumab (MPDL3280A) : 2L+ Par
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
—Randomized Phase: Daratumumab + At
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—Safety Run-in Phase: Daratumumab +
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—
Serious AEs
32.8%a
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 37 more results
42.5%Arm A (Atezo+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
48.3%Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
33.9%
NCT02409342 · Phase 3
53.3%
NCT02367781 · Phase 3 · combination
32.2%
NCT03285763 · Phase 4 · registry result, not featured evidence
32.9%
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
41.1%
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
20.2%1875 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
15.4%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
20.5%1800 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
26.7%1200 mg
NCT03735121 · Phase 3 · registry result, not featured evidence
49%
NCT03191786 · Phase 3 · registry result, not featured evidence
51.2%
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
45.5%Arm A: Atezolizumab + Paclitaxel +
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
50.3%Arm B: Atezolizumab + Nab-Paclitax
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
55.1%
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
55.3%
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
48.5%
NCT04042558 · Phase 2 · registry result, not featured evidence
13.5%Continuation Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
8.4%Crossover Atezolizumab SC
NCT05171777 · Phase 2 · registry result, not featured evidence
100%
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
34.8%
NCT02927301 · Phase 2 · registry result, not featured evidence
17.4%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
10%
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
53.1%
NCT03102242 · Phase 2 · registry result, not featured evidence
17.5%
NCT03526900 · Phase 2 · registry result, not featured evidence
53.3%
NCT02848651 · Phase 2 · registry result, not featured evidence
34.1%Cohort 1: First Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
43.5%Cohort 2: Second Line Atezolizumab
NCT02031458 · Phase 2 · registry result, not featured evidence
44.8%Cohort 3: Third Line and Beyond At
NCT02031458 · Phase 2 · registry result, not featured evidence
37.3%
NCT01903993 · Phase 2 · registry result, not featured evidence
—Atezolizumab (MPDL3280) : 1L Parti
NCT01846416 · Phase 2 · registry result, not featured evidence
54.8%Atezolizumab (MPDL3280A) : 1L Part
NCT01846416 · Phase 2 · registry result, not featured evidence
46.2%Atezolizumab (MPDL3280A) : 2L+ Bra
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
49.5%Atezolizumab (MPDL3280A) : 2L+ Par
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
47.7%Randomized Phase: Daratumumab + At
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
57.1%Safety Run-in Phase: Daratumumab +
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—
Most frequent reported AEs
a
fatigue 27.1%
decreased appetite 24.6%
cough 24%
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 36 more results
alopecia 45%
anaemia 36.5%
nausea 32.5%
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 47.8%
nausea 37.9%
fatigue 34.9%
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 17.5%
decreased appetite 17.5%
fatigue 15.4%
NCT02409342 · Phase 3
anaemia 54.8%
nausea 49.9%
fatigue 48.2%
NCT02367781 · Phase 3 · combination
cough 17.4%
decreased appetite 16.9%
fatigue 16.3%
NCT03285763 · Phase 4 · registry result, not featured evidence
pruritus 22.6%
rash 20.9%
cough 19.7%
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 44.9%
decreased appetite 31.9%
nausea 25.4%
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
1875 mg
anaemia 19%
cough 13.4%
decreased appetite 12.6%
NCT03735121 · Phase 3 · registry result, not featured evidence
1800 mg
asthenia 38.5%
cough 38.5%
diarrhoea 30.8%
NCT03735121 · Phase 3 · registry result, not featured evidence
1800 mg
anaemia 33.3%
fatigue 28.2%
nausea 23.1%
NCT03735121 · Phase 3 · registry result, not featured evidence
1200 mg
anaemia 33.3%
asthenia 20%
blood cholesterol increased 20%
NCT03735121 · Phase 3 · registry result, not featured evidence
decreased appetite 22%
cough 19.7%
fatigue 19.3%
NCT03191786 · Phase 3 · registry result, not featured evidence
anaemia 44.3%
nausea 38.5%
constipation 31.6%
NCT02657434 · Phase 3 · registry result, not featured evidence · combination
anaemia 39.5%
alopecia 39.2%
fatigue 29.2%
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
anaemia 56.3%
nausea 39.2%
neutropenia 36.2%
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
anaemia 52.8%
nausea 39.7%
constipation 33.3%
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
neutrophil count decreased 26.3%
anemia 15.8%
febrile neutropenia 13.2%
NCT04776447 · Phase 2 · registry result, not featured evidence · combination
asthenia 77.9%
nausea 75%
anaemia 64.7%
NCT04042558 · Phase 2 · registry result, not featured evidence
pruritus 9%
arthralgia 7.9%
cough 7.9%
NCT05171777 · Phase 2 · registry result, not featured evidence
injection site reaction 10.3%
diarrhoea 6.5%
asthenia 5.2%
NCT05171777 · Phase 2 · registry result, not featured evidence
atrial flutter 100%
dry mouth 100%
dysplastic naevus 100%
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
fatigue 43.6%
procedural pain 29.8%
dyspnoea 22.7%
NCT02927301 · Phase 2 · registry result, not featured evidence
proteinuria 30.4%
aspartate aminotransferase increased 26.1%
fatigue 26.1%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
neutropenia 50%
alanine aminotransferase increased 6.7%
aspartate aminotransferase increased 6.7%
NCT02716038 · Phase 2 · registry result, not featured evidence · combination
fatigue 65.6%
nausea 53.1%
dyspnea 51.6%
NCT03102242 · Phase 2 · registry result, not featured evidence
fatigue 37.5%
anemia 20%
anorexia 10%
NCT03526900 · Phase 2 · registry result, not featured evidence
fatigue 44.1%
nausea 27.6%
decreased appetite 27%
NCT02848651 · Phase 2 · registry result, not featured evidence
fatigue 37.7%
cough 31.9%
dyspnoea 30.4%
NCT02031458 · Phase 2 · registry result, not featured evidence
fatigue 31.6%
nausea 25.7%
cough 24.5%
NCT02031458 · Phase 2 · registry result, not featured evidence
fatigue 36.5%
cough 32.1%
decreased appetite 29.4%
NCT02031458 · Phase 2 · registry result, not featured evidence
fatigue 38.7%
decreased appetite 35.9%
cough 31.7%
NCT01903993 · Phase 2 · registry result, not featured evidence
fatigue 51.6%
nausea 35.5%
constipation 25.8%
NCT01846416 · Phase 2 · registry result, not featured evidence
constipation 46.2%
fatigue 38.5%
diarrhoea 30.8%
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
fatigue 40.9%
cough 35.5%
dyspnoea 32.3%
NCT01846416 · Phase 2 · registry result, not featured evidence · combination
cough 36.4%
asthenia 31.8%
dyspnoea 29.5%
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 71.4%
hypertension 57.1%
asthenia 42.9%
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for 35 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Atezolizumab

All-cause Mortality 63.8% (n=425) vs 70.1% (n=425) Docetaxel
responder rate · % of participants
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
62.7% (n=241) vs 67.1% (n=222) Docetaxel
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 10.9 vs 10.1 Atezolizumab IV months1875 mg
time to event · months
NCT03735121 · Phase 3 · registry result, not featured evidence
show 28 more results
13.8 vs 9.6 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.7 vs 10.3 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.3 vs 9.8 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.3 vs 10.8 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.6 vs 11.4 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
20.5 vs 9.7 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
19.2 vs 14.7 Bevacizumab+Paclitaxel+Carboplatin months
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
19 vs 14.7 Bevacizumab+Paclitaxel+Carboplatin months
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
20.2 vs 13.1 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
NCT02409342 · Phase 3
18.6 vs 13.9 Nab-Paclitaxel+Carboplatin months
NCT02367781 · Phase 3 · combination
17 vs 13.5 Nab-Paclitaxel+Carboplatin months
NCT02367781 · Phase 3 · combination
NA vs 54.83 Durvalumab months
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
45.57 vs 45.77 Durvalumab months
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
10.7 vs 10.5 Docetaxel months
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
10.3 vs 9.2 Vinorelbine or Gemcitabine months
NCT03191786 · Phase 3 · registry result, not featured evidence
9.4 vs 10.3 Vinorelbine or Gemcitabine months
NCT03191786 · Phase 3 · registry result, not featured evidence
14.2 vs 13.5 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
12.6 vs 13.5 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
20.4 vs 14.5 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
14.8 vs 14.5 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
14.8 vs 15 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
14.9 vs 15 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
18.89 vs 23.1 Pembrolizumab months
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
20.7 vs 33.58 Pembrolizumab months
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
23.79 vs 33.58 Pembrolizumab months
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
17.2 vs 16.8 Cohort Without Bevacizumab months
NCT04042558 · Phase 2 · registry result, not featured evidence
12.6 vs 9.7 Docetaxel months
NCT01903993 · Phase 2 · registry result, not featured evidence
7.13 vs NA Atezolizumab months
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
ORR 11% (n=245) vs 10.5% (n=124) Atezolizumab IV1875 mg
responder rate · % of participants
NCT03735121 · Phase 3 · registry result, not featured evidence
show 17 more results
13.6% (n=425) vs 13.4% (n=425) Docetaxel
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
17.8% (n=241) vs 16.2% (n=222) Docetaxel
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.7% (n=613) vs 11.8% (n=612) Docetaxel
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
38.3% (n=107) vs 28.6% (n=98) Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
NCT02409342 · Phase 3
60.2% (n=452) vs 41% (n=227) Nab-Paclitaxel+Carboplatin
NCT02367781 · Phase 3 · combination
45.5% (n=176) vs 47.5% (n=162) Durvalumab
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
37% (n=184) vs 37.2% (n=191) Durvalumab
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
40.9% (n=335) vs 39.5% (n=324) Durvalumab
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
33.9% (n=369) vs 34.6% (n=376) Durvalumab
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
11.8% (n=186) vs 13.3% (n=180) Docetaxel
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
16.9% (n=302) vs 7.9% (n=151) Vinorelbine or Gemcitabine
NCT03191786 · Phase 3 · registry result, not featured evidence
49.7% (n=342) vs 41% (n=339) Nab-Paclitaxel + Carboplatin
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
49.3% (n=337) vs 41% (n=339) Nab-Paclitaxel + Carboplatin
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
50.2% (n=269) vs 56.6% (n=272) Pembrolizumab
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
0% (n=1) vs 50% (n=4) Atezolizumab
NCT03977467 · Phase 2 · registry result, not featured evidence · combination
15.3% (n=144) vs 14.7% (n=143) Docetaxel
NCT01903993 · Phase 2 · registry result, not featured evidence
4.3% (n=46) vs 13% (n=46) Atezolizumab
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 15.1 vs 11.2 Atezolizumab IV months1875 mg
time to event · months
NCT03735121 · Phase 3 · registry result, not featured evidence
show 16 more results
16.3 vs 6.2 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16 vs 6.2 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
23.9 vs 6.3 Docetaxel months
NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
NA vs 6.7 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
NCT02409342 · Phase 3
43.63 vs 28.09 Durvalumab months
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
36.17 vs 30.16 Durvalumab months
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
36.44 vs 32.39 Durvalumab months
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
35.25 vs 30.16 Durvalumab months
NCT04513925 · Phase 3 · registry result, not featured evidence · combination
5.55 vs 4.3 Docetaxel months
NCT04471428 · Phase 3 · registry result, not featured evidence · combination
14 vs 7.8 Vinorelbine or Gemcitabine months
NCT03191786 · Phase 3 · registry result, not featured evidence
7.2 vs 5.2 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
7 vs 5.2 Nab-Paclitaxel + Carboplatin months
NCT02367794 · Phase 3 · registry result, not featured evidence · combination
9.4 vs 11.1 Pembrolizumab months
NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination
6.25 vs 4.6 Cohort Without Bevacizumab months
NCT04042558 · Phase 2 · registry result, not featured evidence
18.6 vs 7.2 Docetaxel months
NCT01903993 · Phase 2 · registry result, not featured evidence
2.9 vs 5.8 Atezolizumab months
NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination
PFS 8.3 vs 6.8 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
7 vs 5.6 Nab-Paclitaxel+Carboplatin months
ITT Population
NCT02367781 · Phase 3 · combination
Overall Survival 19.8 vs 14.9 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
19 vs 15 Bevacizumab+Paclitaxel+Carboplatin months
ITT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 9 vs 5.7 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT-WT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
ORR 49.3% (n=347) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
responder rate · % of participants
ITT-WT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
63.5% (n=353) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
ITT-WT Population
NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival Rate at 12 64.9% (n=107) vs 50.64% (n=98) Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) @ 52wk
responder rate · % of participants
NCT02409342 · Phase 3
OS Rate at 12 45.49% (n=107) vs 24.79% (n=98) Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) @ 104wk
responder rate · % of participants
NCT02409342 · Phase 3
Time to Deterioration Cough 3.5 vs 3.4 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Cough
NCT02409342 · Phase 3
Time to Deterioration Dyspnea 1.3 vs 1 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
time to event · months
Dyspnea
NCT02409342 · Phase 3
show 1 more result
11.1 vs 11.8 Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) months
Dyspnea
NCT02409342 · Phase 3

+ 833 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atezolizumab's landscape · Sugemalimab's landscape